Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a next generation sequencing based testing laboratory. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Smith David Ross | Corporate Executive VP & CFO | Jan 04 | Sale | 248.76 | 5,000 | 1,243,788 | 15,767 | Jan 05 05:21 PM | LaPlume Joseph W | EVP, Corp Strategy & Develop | Nov 04 | Option Exercise | 123.73 | 6,739 | 833,841 | 18,095 | Nov 05 11:46 AM | LaPlume Joseph W | EVP, Corp Strategy & Develop | Nov 04 | Sale | 250.28 | 6,739 | 1,686,627 | 11,356 | Nov 05 11:46 AM | Barbo William D | Corporate Executive VP & CCO | Nov 03 | Sale | 236.29 | 2,150 | 508,015 | 9,821 | Nov 05 03:51 PM | WALLMAN RICHARD F | Director | Nov 02 | Buy | 233.24 | 6,050 | 1,411,104 | 6,050 | Nov 03 01:21 PM | WALLMAN RICHARD F | Director | Nov 02 | Buy | 232.96 | 1,150 | 267,902 | 31,715 | Nov 03 01:21 PM | FOSTER JAMES C | Chairman, President and CEO | Nov 02 | Sale | 232.38 | 22,000 | 5,112,267 | 186,777 | Nov 03 04:05 PM | MASSARO GEORGE | Director | Sep 14 | Sale | 219.91 | 1,943 | 427,284 | 9,441 | Sep 15 05:47 PM | Girshick Birgit | Corporate Executive VP | Aug 20 | Sale | 213.51 | 933 | 199,205 | 22,852 | Aug 21 10:48 AM | CHUBB STEPHEN D | Director | Aug 18 | Sale | 217.65 | 1,000 | 217,651 | 37,657 | Aug 19 02:48 PM | Knell Michael Gunnar | CSVP&Chief Accounting Officer | Aug 07 | Option Exercise | 111.41 | 3,441 | 383,353 | 5,855 | Aug 10 03:20 PM | Smith David Ross | Corporate Executive VP & CFO | Aug 07 | Option Exercise | 144.67 | 3,304 | 477,990 | 24,071 | Aug 10 04:18 PM | Knell Michael Gunnar | CSVP&Chief Accounting Officer | Aug 07 | Sale | 216.60 | 3,456 | 748,555 | 2,399 | Aug 10 03:20 PM | Smith David Ross | Corporate Executive VP & CFO | Aug 07 | Sale | 216.54 | 3,304 | 715,444 | 20,767 | Aug 10 04:18 PM | Kochevar Deborah Turner | Director | Aug 07 | Sale | 216.24 | 2,319 | 501,467 | 6,728 | Aug 11 10:39 AM | FOSTER JAMES C | Chairman, President and CEO | Aug 07 | Sale | 217.49 | 24,000 | 5,219,771 | 210,777 | Aug 10 04:25 PM | MASSARO GEORGE | Director | May 22 | Sale | 173.40 | 941 | 163,168 | 11,884 | May 26 02:37 PM | BERTOLINI ROBERT J | Director | May 20 | Option Exercise | 52.29 | 3,530 | 184,584 | 32,664 | May 21 11:36 AM | BERTOLINI ROBERT J | Director | May 20 | Sale | 174.58 | 3,530 | 616,263 | 29,134 | May 21 11:36 AM | LaPlume Joseph W | EVP, Corp Strategy & Develop | May 18 | Sale | 174.65 | 350 | 61,128 | 9,637 | May 19 04:18 PM | FOSTER JAMES C | Chairman, President and CEO | May 18 | Sale | 175.00 | 17,435 | 3,051,125 | 229,894 | May 19 04:14 PM | LaPlume Joseph W | EVP, Corp Strategy & Develop | May 15 | Option Exercise | 80.48 | 6,350 | 511,045 | 25,405 | May 19 04:18 PM | LaPlume Joseph W | EVP, Corp Strategy & Develop | May 15 | Sale | 168.26 | 15,418 | 2,594,170 | 9,987 | May 19 04:18 PM | Girshick Birgit | Corporate Executive VP | May 12 | Sale | 165.74 | 780 | 129,277 | 21,837 | May 13 08:18 AM | FOSTER JAMES C | Chairman, President and CEO | May 11 | Sale | 162.53 | 17,446 | 2,835,433 | 249,329 | May 13 11:02 AM | Smith David Ross | Corporate Executive VP & CFO | May 07 | Sale | 150.00 | 1,884 | 282,600 | 18,591 | May 08 10:48 AM | Barbo William D | Corporate Executive VP & CCO | Mar 05 | Option Exercise | 102.56 | 12,467 | 1,278,677 | 30,201 | Mar 06 03:50 PM | Barbo William D | Corporate Executive VP & CCO | Mar 05 | Sale | 164.35 | 13,966 | 2,295,300 | 16,235 | Mar 06 03:50 PM | CHUBB STEPHEN D | Director | Feb 27 | Option Exercise | 55.17 | 7,170 | 395,572 | 42,005 | Feb 28 10:28 AM | CHUBB STEPHEN D | Director | Feb 27 | Sale | 160.89 | 2,464 | 396,437 | 39,541 | Feb 28 10:28 AM | FOSTER JAMES C | Chairman, President and CEO | Feb 26 | Option Exercise | 73.70 | 25,124 | 1,851,639 | 311,899 | Feb 27 02:45 PM | Smith David Ross | Corporate Executive VP & CFO | Feb 26 | Option Exercise | 73.70 | 4,188 | 308,656 | 24,663 | Feb 27 02:48 PM | Smith David Ross | Corporate Executive VP & CFO | Feb 26 | Sale | 162.26 | 4,188 | 679,535 | 20,475 | Feb 27 02:48 PM | FOSTER JAMES C | Chairman, President and CEO | Feb 26 | Sale | 162.25 | 25,124 | 4,076,411 | 286,775 | Feb 27 02:45 PM | FOSTER JAMES C | Chairman, President and CEO | Feb 24 | Option Exercise | 97.80 | 44,303 | 4,332,960 | 333,349 | Feb 26 10:15 AM | Smith David Ross | Corporate Executive VP & CFO | Feb 24 | Option Exercise | 98.02 | 8,211 | 804,860 | 29,065 | Feb 25 11:29 AM | Smith David Ross | Corporate Executive VP & CFO | Feb 24 | Sale | 166.72 | 8,211 | 1,368,953 | 20,854 | Feb 25 11:29 AM | FOSTER JAMES C | Chairman, President and CEO | Feb 24 | Sale | 167.83 | 3,000 | 503,490 | 750 | Feb 26 10:15 AM | FOSTER JAMES C | Chairman, President and CEO | Feb 24 | Sale | 166.70 | 44,303 | 7,385,433 | 289,046 | Feb 26 10:15 AM | MILNE GEORGE M JR | Director | Feb 18 | Option Exercise | 55.17 | 7,170 | 395,572 | 34,207 | Feb 19 10:41 AM | MILNE GEORGE M JR | Director | Feb 18 | Sale | 176.07 | 7,170 | 1,262,430 | 27,037 | Feb 19 10:41 AM | WALLMAN RICHARD F | Director | Feb 14 | Option Exercise | 52.29 | 3,530 | 184,584 | 32,897 | Feb 14 05:10 PM | WALLMAN RICHARD F | Director | Feb 14 | Sale | 174.29 | 3,530 | 615,258 | 29,367 | Feb 14 05:10 PM | BERTOLINI ROBERT J | Director | Feb 13 | Option Exercise | 55.17 | 7,170 | 395,572 | 35,045 | Feb 14 12:24 PM | WALLMAN RICHARD F | Director | Feb 13 | Option Exercise | 55.17 | 7,170 | 395,572 | 36,537 | Feb 14 05:07 PM | BERTOLINI ROBERT J | Director | Feb 13 | Sale | 170.41 | 7,170 | 1,221,819 | 27,875 | Feb 14 12:24 PM | Barbo William D | Corporate Executive VP & CCO | Feb 13 | Sale | 172.11 | 6,901 | 1,187,699 | 18,931 | Feb 14 12:01 PM | FOSTER JAMES C | Chairman, President and CEO | Feb 13 | Sale | 171.90 | 15,000 | 2,578,440 | 298,064 | Feb 14 03:06 PM | Girshick Birgit | Corporate Executive VP | Feb 13 | Sale | 172.05 | 900 | 154,845 | 23,714 | Feb 14 09:43 AM | Smith David Ross | Corporate Executive VP & CFO | Feb 13 | Sale | 170.29 | 4,500 | 766,319 | 21,978 | Feb 13 07:08 PM | WALLMAN RICHARD F | Director | Feb 13 | Sale | 172.02 | 7,170 | 1,233,391 | 29,367 | Feb 14 05:07 PM |
|